CTKB Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -10.48% compared to Cytek Biosciences, Inc.'s net margin of -269.38%. Cytek Biosciences, Inc.'s return on equity of -3.34% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

Cytek Biosciences, Inc. has a consensus price target of $5.75, signalling upside risk potential of 12.75%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1986.96%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than Cytek Biosciences, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than Cytek Biosciences, Inc..

Cytek Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytek Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytek Biosciences, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

Cytek Biosciences, Inc. quarterly revenues are $52.3M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. Cytek Biosciences, Inc.'s net income of -$5.5M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, Cytek Biosciences, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytek Biosciences, Inc. is 3.32x versus 11.43x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -10.48% compared to Cytek Biosciences, Inc.'s net margin of -162.05%. Cytek Biosciences, Inc.'s return on equity of -3.34% beat Standard BioTools, Inc.'s return on equity of -24.44%.

Cytek Biosciences, Inc. has a consensus price target of $5.75, signalling upside risk potential of 12.75%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.65 which suggests that it could fall by -7.74%. Given that Cytek Biosciences, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Cytek Biosciences, Inc. is more attractive than Standard BioTools, Inc..

Cytek Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.585%.

Cytek Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytek Biosciences, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

Cytek Biosciences, Inc. quarterly revenues are $52.3M, which are larger than Standard BioTools, Inc. quarterly revenues of $19.6M. Cytek Biosciences, Inc.'s net income of -$5.5M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, Cytek Biosciences, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytek Biosciences, Inc. is 3.32x versus 4.94x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -10.48% compared to Cytek Biosciences, Inc.'s net margin of -25.94%. Cytek Biosciences, Inc.'s return on equity of -3.34% beat LENSAR, Inc.'s return on equity of -1013.45%.

Cytek Biosciences, Inc. has a consensus price target of $5.75, signalling upside risk potential of 12.75%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 24.48%. Given that LENSAR, Inc. has higher upside potential than Cytek Biosciences, Inc., analysts believe LENSAR, Inc. is more attractive than Cytek Biosciences, Inc..

Cytek Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.665, suggesting its less volatile than the S&P 500 by 33.53%.

Cytek Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytek Biosciences, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

Cytek Biosciences, Inc. quarterly revenues are $52.3M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Cytek Biosciences, Inc.'s net income of -$5.5M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Cytek Biosciences, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytek Biosciences, Inc. is 3.32x versus 2.41x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Movano, Inc. has a net margin of -10.48% compared to Cytek Biosciences, Inc.'s net margin of -5036.25%. Cytek Biosciences, Inc.'s return on equity of -3.34% beat Movano, Inc.'s return on equity of -410.28%.

Cytek Biosciences, Inc. has a consensus price target of $5.75, signalling upside risk potential of 12.75%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 3536.36%. Given that Movano, Inc. has higher upside potential than Cytek Biosciences, Inc., analysts believe Movano, Inc. is more attractive than Cytek Biosciences, Inc..

Cytek Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytek Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytek Biosciences, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

Cytek Biosciences, Inc. quarterly revenues are $52.3M, which are larger than Movano, Inc. quarterly revenues of $80K. Cytek Biosciences, Inc.'s net income of -$5.5M is lower than Movano, Inc.'s net income of -$4M. Notably, Cytek Biosciences, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytek Biosciences, Inc. is 3.32x versus 12.49x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.